How do lipitor generics compare in cost?

How much cheaper are Lipitor generics than the brand?

Generic atorvastatin typically costs 80 to 90 percent less than brand-name Lipitor. Current retail prices for a 30-day supply of 20 mg tablets show brand Lipitor at roughly $450, while generic versions range from $10 to $30. Savings are consistent across most major pharmacies.

When does the Lipitor patent expire?

The primary compound patent for atorvastatin expired in 2011, opening the door for generic manufacturers to enter the market. Multiple companies now produce the drug, increasing competition and driving prices down.

Why are Lipitor generics so much cheaper?

Once the patent expired, any manufacturer that demonstrates bioequivalence to the original drug can sell it under an abbreviated new drug application. They avoid the billions spent on research and drug discovery, so they can sell the product at far lower prices. The abundance of suppliers further lowers market prices.

How do Lipitor generics compare with other statins?

Atorvastatin ranks among the most commonly prescribed statins, but it differs from other options such as rosuvastatin (Crestor) and pravastatin. Its half-life and potency profile place it between simvastatin and rosuvastatin. Patients who switch from Lipitor to generic atorvastatin usually report no difference in cholesterol-lowering effect.

What factors affect the price of Lipitor generics?

Pharmacy type, insurance coverage, discount programs, and location influence final cost. Many retailers offer $4 or $10 monthly programs for generic atorvastatin. Online pharmacies and mail-order services can deliver further savings, but users should verify that they obtain a genuine product from a reliable source.

Can biosimilars enter before patent expiry?

Atorvastatin is a small-molecule drug rather than a biologic, so no biosimilars exist. Generic versions entered immediately after patent expiry in 2011 and continue to supply the market.

Why are companies challenging this patent?

The original manufacturer pursued additional patents on specific salt forms and formulations after the compound patent expired. Some manufacturers challenged these later patents in court, but most challenges did not reopen exclusivity because the core compound patent had already lapsed.